142 related articles for article (PubMed ID: 7664496)
1. The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) mice.
Walker W; Gallagher G
Clin Exp Immunol; 1995 Sep; 101(3):494-501. PubMed ID: 7664496
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model.
Schultes BC; Zhang C; Xue LY; Noujaim AA; Madiyalakan R
Hybridoma; 1999 Feb; 18(1):47-55. PubMed ID: 10211788
[TBL] [Abstract][Full Text] [Related]
3. The in vivo production of specific human antibodies by vaccination of human-PBL-SCID mice.
Walker W; Gallagher G
Immunology; 1994 Oct; 83(2):163-70. PubMed ID: 7530687
[TBL] [Abstract][Full Text] [Related]
4. [Establishment and comparison of two intraperitoneally transplanted human ovarian carcinoma models with immune reconstitution in severe combined immunodeficient mice].
Li Y; Cui H; Chang XH; Feng J; Fu TY; Feng YJ; Wei LH
Ai Zheng; 2004 Feb; 23(2):160-4. PubMed ID: 14960235
[TBL] [Abstract][Full Text] [Related]
5. Establishment of human IgE system in severe combined immunodeficient mice with peripheral blood mononuclear cells from asthmatic children.
Chiang BL; Chou CC; Ding HJ; Huang MS; Chen JM; Hsieh KH
J Allergy Clin Immunol; 1995 Jan; 95(1 Pt 1):69-76. PubMed ID: 7822666
[TBL] [Abstract][Full Text] [Related]
6. Anti-tetanus toxoid antibody production and protection against lethal doses of tetanus toxin in hu-PBL-SCID mice.
Naito S; Okada Y; Takahashi M; Kato H; Taneichi M; Ami Y; Suzaki Y; Oka T; Okuma K; Morokuma K; Onodera H; Inoue M; Takahashi Y; Yamazaki S; Kimura H; Komuro K; Uchida T
Int Arch Allergy Immunol; 2000 Oct; 123(2):149-54. PubMed ID: 11060487
[TBL] [Abstract][Full Text] [Related]
7. Antibody responses to Toxoplasma gondii antigen in human peripheral blood lymphocyte-reconstituted severe-combined immunodeficient mice reproduce the immunological status of the lymphocyte donor.
Walker W; Roberts CW; Brewer JM; Alexander J
Eur J Immunol; 1995 May; 25(5):1426-30. PubMed ID: 7774646
[TBL] [Abstract][Full Text] [Related]
8. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
[TBL] [Abstract][Full Text] [Related]
9. [Specific immune cell therapy against ovarian cancer in vivo and in vitro].
Chang XH; Cheng HY; Cheng YX; Ye X; Guo HF; Fu TY; Zhang L; Zhang G; Cui H
Ai Zheng; 2008 Dec; 27(12):1244-50. PubMed ID: 19079987
[TBL] [Abstract][Full Text] [Related]
10. Limited B cell repertoire in severe combined immunodeficient mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans.
Saxon A; Macy E; Denis K; Tary-Lehmann M; Witte O; Braun J
J Clin Invest; 1991 Feb; 87(2):658-65. PubMed ID: 1991850
[TBL] [Abstract][Full Text] [Related]
11. Murine IL-2 receptor beta chain blockade improves human leukocyte engraftment in SCID mice.
Tournoy KG; Depraetere S; Meuleman P; Leroux-Roels G; Pauwels RA
Eur J Immunol; 1998 Oct; 28(10):3221-30. PubMed ID: 9808191
[TBL] [Abstract][Full Text] [Related]
12. Human peripheral blood lymphocyte reconstituted severe combined immunodeficient (hu-PBL-SCID) mice. A model for human islet allograft rejection.
Shiroki R; Poindexter NJ; Woodle ES; Hussain MS; Mohanakumar T; Scharp DW
Transplantation; 1994 Jun; 57(11):1555-62. PubMed ID: 8009588
[TBL] [Abstract][Full Text] [Related]
13. Establishment of a cervical cancer model via inoculating SiHa Cells into humanized severe combined immunodeficient mice.
Ye F; Chen H; Liang Z; Lu W; Cheng Q; Xie X
Eur J Gynaecol Oncol; 2006; 27(6):566-72. PubMed ID: 17290584
[TBL] [Abstract][Full Text] [Related]
14. [Development of intraperitoneally transplantated human ovarian carcinoma model with immune reconstruction in severe combined immunodeficient mice].
Zhu H; Ye D; Chen H; Lu W; Xie X
Zhonghua Yi Xue Za Zhi; 2002 May; 82(9):630-3. PubMed ID: 12133487
[TBL] [Abstract][Full Text] [Related]
15. Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactive antibodies.
Williams SS; Umemoto T; Kida H; Repasky EA; Bankert RB
J Immunol; 1992 Oct; 149(8):2830-6. PubMed ID: 1401915
[TBL] [Abstract][Full Text] [Related]
16. The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy.
Boyle MJ; Connors M; Flanigan ME; Geiger SP; Ford H; Baseler M; Adelsberger J; Davey RT; Lane HC
J Immunol; 1995 Jun; 154(12):6612-23. PubMed ID: 7759895
[TBL] [Abstract][Full Text] [Related]
17. [Immuno-therapeutic study of anti-idiotype minibody (single chain Fv-CH3) on ovarian carcinoma bearing mice].
Li Y; Chang XH; Cui H; Yang WL; Feng J; Wei LH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug; 25(4):451-6. PubMed ID: 12974094
[TBL] [Abstract][Full Text] [Related]
18. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
19. Growth of human tumor-cell lines in immunodeficient scid and immune reconstituted human-pbl-scid mice - an improved in-vivo model for the study of human malignancy.
Walker W
Int J Oncol; 1995 Nov; 7(5):1227-32. PubMed ID: 21552955
[TBL] [Abstract][Full Text] [Related]
20. Specific antibody production to a recall or a neoantigen by SCID mice reconstituted with human peripheral blood lymphocytes.
Nonoyama S; Smith FO; Ochs HD
J Immunol; 1993 Oct; 151(7):3894-901. PubMed ID: 8376809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
